Disruption of MEF2C Signaling and Loss of Sarcomeric and Mitochondrial Integrity in Cancer-induced Skeletal Muscle Wasting

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2012 Feb 25

PMID 22361433

Citations 54

Authors

Angie M Y Shum

Theodore Mahendradatta

Ryland J Taylor

Arran B Painter

Melissa M Moore

Maria Tsoli

Timothy C Tan

Stephen J Clarke

Graham R Robertson

Patsie Polly

Affiliations

Soon will be listed here.

Abstract

Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Loss of skeletal muscle is a defining characteristic of patients with cancer cachexia and is associated with poor survival. The present study reveals the involvement of a myogenic transcription factor Myocyte Enhancer Factor (MEF) 2C in cancer-induced skeletal muscle wasting. Increased skeletal muscle mRNA expression of Suppressor of Cytokine Signaling (Socs) 3 and the IL-6 receptor indicative of active IL-6 signaling was seen in skeletal muscle of mice bearing the Colon 26 (C26) carcinoma. Loss of skeletal muscle structural integrity and distorted mitochondria were also observed using electron microscopy. Gene and protein expression of MEF2C was significantly downregulated in skeletal muscle from C26-bearing mice. MEF2C gene targets myozenin and myoglobin as well as myokinase were also altered during cachexia, suggesting dysregulated oxygen transport capacity and ATP regeneration in addition to distorted structural integrity. In addition, reduced expression of calcineurin was observed which suggested a potential pathway of MEF2C dysregulation. Together, these effects may limit sarcomeric contractile ability and also predispose skeletal muscle to structural instability; associated with muscle wasting and fatigue in cachexia.

Citing Articles

Machine learning-random forest model was used to construct gene signature associated with cuproptosis to predict the prognosis of gastric cancer.

Liu X, Tao P, Su H, Li Y Sci Rep. 2025; 15(1):4170.

PMID: 39905263 PMC: 11794614. DOI: 10.1038/s41598-025-88812-9.

Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour-bearing mice.

Massart I, Kouakou A, Pelet N, Lause P, Schakman O, Loumaye A J Cachexia Sarcopenia Muscle. 2024; 15(3):919-933.

PMID: 38572511 PMC: 11154773. DOI: 10.1002/jcsm.13454.

The Role of Exercise in Cancer-Related Sarcopenia and Sarcopenic Obesity.

Papadopetraki A, Giannopoulos A, Maridaki M, Zagouri F, Droufakou S, Koutsilieris M Cancers (Basel). 2023; 15(24).

PMID: 38136400 PMC: 10741686. DOI: 10.3390/cancers15245856.

Effect of insulin insufficiency on ultrastructure and function in skeletal muscle.

Kopecky C, Haug M, Reischl B, Deshpande N, Manandhar B, King T J Cachexia Sarcopenia Muscle. 2023; 15(1):112-123.

PMID: 38124345 PMC: 10834341. DOI: 10.1002/jcsm.13380.

Red Flags in Primary Mitochondrial Diseases: What Should We Recognize?.

Conti F, Di Martino S, Drago F, Bucolo C, Micale V, Montano V Int J Mol Sci. 2023; 24(23).

PMID: 38069070 PMC: 10706469. DOI: 10.3390/ijms242316746.

References

Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E . Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res. 1995; 55(4):921-7. View

Bassel-Duby R, Hernandez M, Gonzalez M, Krueger J, Williams R . A 40-kilodalton protein binds specifically to an upstream sequence element essential for muscle-specific transcription of the human myoglobin promoter. Mol Cell Biol. 1992; 12(11):5024-32. PMC: 360435. DOI: 10.1128/mcb.12.11.5024-5032.1992. View

Zaki M, Nemeth J, Trikha M . CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer. 2004; 111(4):592-5. DOI: 10.1002/ijc.20270. View

Frey N, Richardson J, Olson E . Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci U S A. 2000; 97(26):14632-7. PMC: 18970. DOI: 10.1073/pnas.260501097. View

Lecker S, Jagoe R, Gilbert A, Gomes M, Baracos V, Bailey J . Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004; 18(1):39-51. DOI: 10.1096/fj.03-0610com. View

STRASSMANN G, Jacob C, Fong M, Bertolini D . Mechanisms of paraneoplastic syndromes of colon-26: involvement of interleukin 6 in hypercalcemia. Cytokine. 1993; 5(5):463-8. DOI: 10.1016/1043-4666(93)90037-6. View

Janssen E, Dzeja P, Oerlemans F, Simonetti A, Heerschap A, de Haan A . Adenylate kinase 1 gene deletion disrupts muscle energetic economy despite metabolic rearrangement. EMBO J. 2000; 19(23):6371-81. PMC: 305872. DOI: 10.1093/emboj/19.23.6371. View

Levine S . Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem. 2008; 283(21):14177-81. PMC: 2386928. DOI: 10.1074/jbc.R700052200. View

Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y . Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 2007; 69(1):113-7. DOI: 10.1016/j.urology.2006.09.039. View

10.

Acharyya S, Butchbach M, Sahenk Z, Wang H, Saji M, Carathers M . Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005; 8(5):421-32. DOI: 10.1016/j.ccr.2005.10.004. View

11.

Rui L, Yuan M, Frantz D, Shoelson S, White M . SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002; 277(44):42394-8. DOI: 10.1074/jbc.C200444200. View

12.

Petersen A, Pedersen B . The anti-inflammatory effect of exercise. J Appl Physiol (1985). 2005; 98(4):1154-62. DOI: 10.1152/japplphysiol.00164.2004. View

13.

Iwase S, Murakami T, Saito Y, Nakagawa K . Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw. 2005; 15(4):312-6. View

14.

Heinrich P, Behrmann I, Haan S, Hermanns H, Muller-Newen G, Schaper F . Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374(Pt 1):1-20. PMC: 1223585. DOI: 10.1042/BJ20030407. View

15.

Baltgalvis K, Berger F, Pena M, Davis J, Muga S, Carson J . Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol. 2007; 294(2):R393-401. DOI: 10.1152/ajpregu.00716.2007. View

16.

Gupta A, Gupta S, Young D, Das B, McMahon J, Sen S . Impairment of ultrastructure and cytoskeleton during progression of cardiac hypertrophy to heart failure. Lab Invest. 2010; 90(4):520-30. DOI: 10.1038/labinvest.2010.43. View

17.

Meinhardt . Olson EN, williams RS. Remodeling muscles with calcineurin. Bioessays 2000;22:510-519. Bioessays. 2000; 22(11):1049. DOI: 10.1002/1521-1878(200011)22:11<1049::AID-BIES14>3.0.CO;2-M. View

18.

Zohlnhofer D, Graeve L, Rose-John S, Schooltink H, Dittrich E, Heinrich P . The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett. 1992; 306(2-3):219-22. DOI: 10.1016/0014-5793(92)81004-6. View

19.

Kanatous S, Mammen P . Regulation of myoglobin expression. J Exp Biol. 2010; 213(Pt 16):2741-7. PMC: 2912755. DOI: 10.1242/jeb.041442. View

20.

Abbatecola A, Paolisso G, Fattoretti P, Evans W, Fiore V, Dicioccio L . Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging. 2011; 15(10):890-5. DOI: 10.1007/s12603-011-0366-0. View